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olaratumab using an ELISA method at ICON Laboratory Services, Inc. (Whitesboro, NY, USA). Olaratumab was stable for up to 1052 days when stored at approximately -70°C.
Pharmacokinetic Analysis
Pharmacokinetic parameters for olaratumab and doxorubicin were determined using noncompartmental methods using Phoenix WinNonlin (Version 6.4., Cetara, Princeton, NY) . Pharmacokinetic parameters of doxorubicin were determined after cycle 1, day 1 (doxorubicin alone) and cycle 2, day 1 (olaratumab + doxorubicin) doses (Supplemental Table 1 ).
The same parameters were determined for olaratumab after cycle 1, day 10 (olaratumab alone) and cycle 2, day 1 (olaratumab + doxorubicin) doses of olaratumab, except that the following parameters were calculated in place of AUC(0-∞), which could not be calculated reliably due to a large number of AUC(0-∞) determinations with an extrapolation of >20%: AUC from 0 to 168 hours postdose (AUC0-168h) and AUC from 0 to 288 hours postdose (AUC0-288h) were calculated at cycle 1, day 10 and AUC0-168h and AUC from 0 to 336 hours postdose (AUC0-336h) were calculated at cycle 2, day 1. Actual sampling times relative to the start of the infusion of olaratumab (for olaratumab PK parameters) or doxorubicin (for doxorubicin PK parameters) were used in the analyses of individual PK parameters, with the exception of pre-first-dose sampling times on the first dosing day, which were set to zero. Plasma or serum concentration values below the LLOQ were excluded from the analysis. For graphical assessment, average concentrations at any individual time point were only calculated if at least two thirds of the individual data were above the LLOQ.
Supplemental Table 1. Estimated Pharmacokinetic Parameters
Parameter Description %AUC(t last -∞) * Fraction of area under the concentration versus time curve from zero to infinity (0-∞) extrapolated. AUC(0-∞) * Area under the concentration versus time curve from zero to infinity. AUC(0-t last ) * AUC from time zero to the last time point with a measurable concentration. AUC0-168h # Area under the concentration versus time curve from 0 to 168 hours. AUC0-288h # Area under the concentration versus time curve from 0 to 288 hours. AUC0-336h # Area under the concentration versus time curve from 0 to 336 hours. CL Apparent total body clearance of drug calculated after IV administration.
Cmax
Maximum observed drug concentration. 
